Switch theme
Sign up to access all valuation multiples
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. Its product (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. Its other products CT002 which is a Non-invasive nasal spray and CT003 which is a local anaesthetic gel are in different stages development.
2020
4
LTM Revenue n/a
LTM EBITDA n/a
$18.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cessatech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cessatech achieved revenue of $0.4M and an EBITDA of -$2.7M.
Cessatech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cessatech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $0.4M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$3.2M | -$2.7M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -766% | XXX | XXX | XXX |
| Net Profit | -$2.1M | -$3.8M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -1067% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cessatech's stock price is DKK 8 (or $1).
Cessatech has current market cap of DKK 144M (or $20.7M), and EV of DKK 131M (or $18.9M).
See Cessatech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18.9M | $20.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cessatech has market cap of $20.7M and EV of $18.9M.
Cessatech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cessatech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cessatech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $18.9M | XXX | XXX | XXX |
| EV/Revenue | 52.8x | XXX | XXX | XXX |
| EV/EBITDA | -6.9x | XXX | XXX | XXX |
| P/E | -9.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -18.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCessatech's NTM/LTM revenue growth is n/a
Cessatech's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Cessatech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cessatech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cessatech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -766% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -15% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 866% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cessatech acquired XXX companies to date.
Last acquisition by Cessatech was XXXXXXXX, XXXXX XXXXX XXXXXX . Cessatech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cessatech founded? | Cessatech was founded in 2020. |
| Where is Cessatech headquartered? | Cessatech is headquartered in Sweden. |
| How many employees does Cessatech have? | As of today, Cessatech has 4 employees. |
| Is Cessatech publicy listed? | Yes, Cessatech is a public company listed on SAT. |
| What is the stock symbol of Cessatech? | Cessatech trades under CESSA ticker. |
| When did Cessatech go public? | Cessatech went public in 2020. |
| Who are competitors of Cessatech? | Similar companies to Cessatech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cessatech? | Cessatech's current market cap is $20.7M |
| Is Cessatech profitable? | Yes, Cessatech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
